https://www.selleckchem.com/products/rcm-1.html
A quasi-experimental research design was utilized in this study. Significant differences were found between the study and control groups immediately post and after 3months of ACT on baseline PSYRATS VAAS scores. ACT offers a promising new treatment for auditory hallucination among patients with schizophrenia. A significant improvement in auditory hallucination was found in the study group immediately after implementing ACT and after 3months. As well as a decrement in re hospitalization rate and improvement in drug compliance for the
Like
Comment
Share
